LXRX Panoramica delle azioni Lexicon Pharmaceuticals, Inc. è una società biofarmaceutica che si concentra sulla scoperta, lo sviluppo e la commercializzazione di prodotti farmaceutici. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Lexicon Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Lexicon Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$0.76 Massimo di 52 settimane US$3.73 Minimo di 52 settimane US$0.62 Beta 1.06 Variazione di 1 mese -12.23% Variazione a 3 mesi -49.81% Variazione di 1 anno -46.26% Variazione a 3 anni -81.91% Variazione a 5 anni -81.74% Variazione dall'IPO -99.42%
Notizie e aggiornamenti recenti
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) Dec 21
Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Nov 26
Price target decreased by 13% to US$4.68 Nov 22
Lexicon Pharmaceuticals, Inc. Announces Board Changes Nov 21
Consensus revenue estimates decrease by 24% Nov 20
New major risk - Financial position Nov 15 Vedi altri aggiornamenti
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) Dec 21
Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Nov 26
Price target decreased by 13% to US$4.68 Nov 22
Lexicon Pharmaceuticals, Inc. Announces Board Changes Nov 21
Consensus revenue estimates decrease by 24% Nov 20
New major risk - Financial position Nov 15
Price target increased by 16% to US$6.25 Nov 14
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 13
Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease Nov 06 Lexicon Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024
Price target decreased by 16% to US$5.40 Nov 03
Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease Nov 02
Consensus revenue estimates increase by 33% Oct 18
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes Oct 16
Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress Sep 27 Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer
Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial Sep 04
Consensus revenue estimates decrease by 41% Aug 09
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money Aug 08
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success Aug 03
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 02
Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission Jul 17
Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure Jul 15
High number of new directors Jul 10
Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer Jul 09 Lexicon Pharmaceuticals, Inc. Announces CEO Changes
Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association Jun 19
Price target increased by 13% to US$6.20 Jun 18
Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much May 28
Lexicon Pharmaceuticals, Inc. Announces A New Post-Hoc Analysis of Clinical Data Showing That Inpefa® (Sotagliflozin), A Dual Oral Inhibitor of Sglt2 and Sglt1, Reduced the Risk of Heart Failure-Related Events Across A Diverse Population of Patients, Including Patients with Preserved Ejection Fraction May 15
New major risk - Shareholder dilution May 13
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 03
Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024 May 01 Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024
Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024 Mar 27
Consensus revenue estimates decrease by 44%, EPS upgraded Mar 18 Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A. Mar 14
New major risk - Share price stability Mar 12
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease Mar 12
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset Mar 12
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Mar 12 Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors. Mar 11
CEO & Director exercised options and sold US$161k worth of stock Mar 01
Consensus revenue estimates fall by 54% Feb 16
Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do Jan 26
Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference Jan 09
Consensus revenue estimates decrease by 12% Dec 14
Price target decreased by 7.2% to US$5.15 Dec 13
Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain Nov 30
Independent Director recently bought US$202k worth of stock Nov 17
Consensus revenue estimates decrease by 31%, EPS upgraded Nov 15
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10
Price target increased by 30% to US$7.50 Nov 09
Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 04
Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023 Nov 01
Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting Oct 18
Independent Chairman of the Board recently bought US$1.1m worth of stock Oct 13
Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023 Oct 12
New minor risk - Share price stability Oct 11 Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients
Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes Sep 27
Consensus EPS estimates fall by 18% Aug 11
Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure Aug 09
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money Aug 08
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 04 Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors
Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023 Jul 25
CEO & Director recently bought US$92k worth of stock Jun 24
Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions Jun 21
Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure Jun 17 Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC Jun 07
Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC Jun 06
Lexicon Pharmaceuticals, Inc. announced that it expects to receive $62.795767 million in funding from The Invus Group, LLC Jun 03
Rendimenti per gli azionisti LXRX US Biotechs US Mercato 7D 3.2% -3.3% -0.4% 1Y -46.3% -2.7% 24.8%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: LXRX ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento -2.7 % nell'ultimo anno.
Rendimento vs Mercato: LXRX ha avuto una performance inferiore al mercato US che ha registrato un rendimento 24.8 % nell'ultimo anno.
Volatilità dei prezzi Is LXRX's price volatile compared to industry and market? LXRX volatility LXRX Average Weekly Movement 16.9% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Prezzo delle azioni stabile: Il prezzo delle azioni di LXRX è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 17% ) di LXRX è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda Lexicon Pharmaceuticals, Inc. è una società biofarmaceutica che si occupa della scoperta, dello sviluppo e della commercializzazione di prodotti farmaceutici. I suoi candidati farmaci a base di piccole molecole a somministrazione orale in fase di sviluppo comprendono Sotagliflozin, che ha completato gli studi clinici di Fase III per il trattamento dell'insufficienza cardiaca e del diabete di tipo 1; LX9211, che è in fase di sviluppo clinico di Fase II per il trattamento del dolore neuropatico e LX2761, che è in fase di sviluppo clinico di Fase I per il tratto gastrointestinale. Lexicon Pharmaceuticals, Inc. ha accordi di collaborazione strategica e di licenza con Bristol-Myers Squibb Company e Genentech, Inc. La società è stata costituita nel 1995 e ha sede a The Woodlands, in Texas.
Mostra di più Lexicon Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Lexicon Pharmaceuticals con la sua capitalizzazione di mercato? LXRX statistiche fondamentali Capitalizzazione di mercato US$273.94m Guadagni(TTM ) -US$216.39m Ricavi(TTM ) US$5.23m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) LXRX Conto economico (TTM ) Ricavi US$5.23m Costo del fatturato US$72.90m Profitto lordo -US$67.67m Altre spese US$148.73m Guadagni -US$216.39m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.60 Margine lordo -1,294.05% Margine di profitto netto -4,138.32% Rapporto debito/patrimonio netto 56.0%
Come si è comportato LXRX nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/24 17:30 Prezzo dell'azione a fine giornata 2024/12/24 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Lexicon Pharmaceuticals, Inc. è coperta da 15 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Yigal Nochomovitz Citigroup Inc Kevin Kedra G. Research, LLC Joseph Pantginis H.C. Wainwright & Co.
Mostra 12 altri analisti 
